Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Return on Sales (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Return on Sales readings, the most recent being 0.08% for Q1 2026.

  • On a quarterly basis, Return on Sales fell 8.0% to 0.08% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.02%, a 2.0% decrease, with the full-year FY2025 number at 0.0%, up 1.0% from a year prior.
  • Return on Sales hit 0.08% in Q1 2026 for Atara Biotherapeutics, up from 0.23% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.0% in Q1 2025 to a low of 3.38% in Q4 2022.
  • Median Return on Sales over the past 5 years was 0.05% (2025), compared with a mean of 0.36%.
  • The widest YoY moves for Return on Sales: up 325bps in 2023, down -90bps in 2023.
  • Atara Biotherapeutics' Return on Sales stood at 3.38% in 2022, then surged by 96bps to 0.12% in 2023, then surged by 97bps to 0.0% in 2024, then crashed by -5747bps to 0.23% in 2025, then skyrocketed by 65bps to 0.08% in 2026.
  • The last three reported values for Return on Sales were 0.08% (Q1 2026), 0.23% (Q4 2025), and 0.01% (Q3 2025) per Business Quant data.